



Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

Date: 03/01/2025

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051, Maharashtra, India.

NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013

Subj: Clarification for Financial results.

Ref: NSE email dated January 02, 2025.

Dear Sir/Ma'am,

With reference to the above subject this is for the clarification as required by the company for the half year ended on September 30, 2024:

1. Segment details not submitted

Reply: The company's business activity falls within a single primary business segment, the disclosure requirements as per AS 17 "Segment Reporting" is not applicable. As a result, the disclosure pertaining to the multiple segments does not apply to the company. Please also take note that we chose the "single segment" option while preparing the company's result in "XBRL" format.

2. Machine Readable Form / Legible copy of Financial Results not submitted

Reply: Please find enclosed herewith the Machine-Readable Form / Legible copy of the financial results of the Company for the half year ended September 30, 2024.

We hope this reply will satisfy your query. Please take the above clarification on record.

We shall be grateful to you for your understanding and cooperation in the said matter.

Thanking you
Yours faithfully

For, ZENITH DRUGS LIMITED

SAKSHI BHAWSAR
Company Secretary and Compliance Officer

V D S & CO.
CHARTERED ACCOUNTANT



201, Earth Avenue, 7
Bamru Colony, Jaora Compound
Indore- 452001, Ph. (O) 4046319

Auditor's Limited Review Report on unaudited Standalone Financial Results of Zenith Drugs Limited for the half year ended September 30, 2024 pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors of
Zenith Drugs Limited

We have reviewed the accompanying statement of unaudited financial results of Zenith Drugs Limited ("the Company") for the period ended September 30, 2024 attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14.11.2024
Place: Indore

For, V D S & Co
Chartered Accountants
FRN: 004029C

D. S. Dhing
(Partner)
M. No. 075588
UDIN: 24075588BKEYXC5479

STATEMENT OF STANDALONE BALANCE SHEET AS ON September, 30th 2024

(Amount In Lakhs)

Sr. No.	Particulars	As on September 30, 2024	As at March 31, 2024
		Unaudited	Audited
I.	<u>EQUITY AND LIABILITIES</u>		
1	Shareholders' funds	1,714.88	1,714.88
	(a) Share capital	5,078.85	4,506.98
	(b) Reserves and Surplus		
2	Non-current liabilities	1,592.47	785.28
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (Net)		
3	Current liabilities	2,361.82	1,608.01
	(a) Short-term borrowings	3,054.96	4,263.08
	(b) Trade payables	-	86.57
	-Due to Micro, Small and Medium Enterprises	-	4,176.51
	-Due to Other Than MSME	72.95	68.24
	(c) Other Current Liabilities	486.91	470.69
	(d) Short-term provisions		
	TOTAL	14,362.83	13,417.16
II.	<u>ASSETS</u>		
1	Non-current assets		
	(a) Property, Plant and Equipment & Intangible assets	1,110.49	1,093.55
	(i) Property, Plant and Equipment	0.64	0.74
	(ii) Intangible assets	2,091.15	390.67
	(iii) Capital work in Progress	-	2.55
	(b) Non-Current Investment	6.56	6.56
	(b) Deferred tax assets (Net)	278.34	639.58
	(c) Long-term loans and advances	-	-
	(d) Other Non-current assets		
2	Current assets	2,952.70	2,575.83
	(a) Inventories	6,371.99	6,739.45
	(b) Trade receivables	96.22	874.29
	(c) Cash and Cash Equivalents	1,138.17	795.13
	(d) Short-term loans and advances	316.58	298.82
	(e) Other current assets		
	TOTAL	14,362.83	13,417.16

For Zenith Drugs Limited,

SANDEEP BHARDWAJ
Managing Director
(DIN: 00539347)

For Zenith Drugs Limited

Neeraj Pandey
CFO

Place: Indore
Date : 14/11/2024

ZENITH DRUGS LIMITED
72/5, Muradpura (Orangpura) Dhar Road, Near Kalaria, INDORE, PIN-453001 (M.P.)
CIN No.- U24231MP2000PLC014465
STATEMENT OF STANDALONE PROFIT & LOSS AS ON September, 30th 2024

(Amount In Lakhs)

		(Amount in Lakhs)				
Sr. No.	Particulars	Half Yearly ended			Yearly ended	
		Half Yearly ended on 30.09.2024	Half Yearly ended on 30.09.2023	Half Yearly ended on 31.03.2024	As at March 31, 2024	As at March 31, 2023
		Unaudited	Audited	Audited	Audited	Audited
A. CONTINUING OPERATIONS						
I.	Income from operations	6,769.48	6,940.93	6,221.04	13,161.97	11,451.91
II.	Other income	86.61	7.50	204.72	212.22	123.92
III.	Total Revenue (I + II)	6,856.09	6,948.43	6,425.75	13,374.18	11,575.83
IV.	Expenses:					
(a)	Cost of Materials Consumed	4,685.87	4,022.03	4,392.49	8,414.52	7,866.37
(b)	Changes in inventories of Finished Goods & W-I-P	(19.76)	140.30	(4.10)	136.20	(54.24)
(c)	Other Operating Expenses	430.15	407.61	382.08	789.69	701.06
(d)	Employee benefits expense	335.01	328.82	279.74	608.56	491.20
(e)	Finance costs	124.08	145.76	153.95	299.71	232.72
(f)	Depreciation and amortization expense	68.62	63.27	66.96	130.23	130.46
(g)	Other expenses	660.25	933.21	587.60	1,520.81	1,542.52
	Total expenses	6,284.22	6,041.00	5,858.71	11,899.71	10,910.09
V.	Profit before Exceptional & Extraordinary Items	571.87	907.43	567.04	1,474.47	665.74
VI.	Exceptional Items	-	-	-	-	-
	Profit before Extraordinary Items & Tax	571.87	907.43	567.04	1,474.47	665.74
VII.	Extraordinary Items	-	143.88	1.37	145.25	-
VIII.	Profit Before Tax	571.87	763.55	565.67	1,329.22	665.74
IX.	Tax expense:					
	(1) Current tax	-	197.16	187.79	384.94	175.81
	(2) Deferred tax	-	(3.70)	(20.07)	(23.77)	(5.12)
	(3) Earlier Year Tax Expense	-	-	14.37	14.37	6.95
		-	193.45	182.09	375.54	177.63
X.	Profit(Loss) for the year from continuing operations (VIII-IX)	571.87	570.10	383.59	953.69	488.11
XI.	Profit/(Loss) from discontinuing operations	-	-	-	-	-
XII.	Tax expense of discounting operations	-	-	-	-	-
XIII.	Profit/(Loss) from Discontinuing operations)(XI - XII)	-	-	-	-	-
XIV.	Profit/(Loss) for the year (X + XIII)	571.87	570.10	383.59	953.69	488.11
XV.	Earnings per equity share:					
(i)	Basic EPS					
(a)	Continuing operations	3.33	4.75	4.56	5.56	122.03
(b)	Total operations	3.33	4.75	4.56	5.56	122.03
(ii)	Diluted EPS					
(a)	Continuing operations	3.33	4.75	4.56	5.56	122.03
(b)	Total operations	3.33	4.75	4.56	5.56	122.03

For Zenith Drugs Limited
For Zenith Drugs Limited,

SANDEEP BHARDWAJ
Managing Director
(DIN: 00539347)

For Zenith Drugs Limited

Neeraj Pandey
CFO

Place: Indore
Date : 14/11/2024

ZENITH DRUGS LIMITED
CIN No.- U24231MP2000PLC014465

STATEMENT OF STANDALONE CASH FLOW for the period ending on September, 30th 2024

(Amount In Lakhs)

1	CASH FLOW FROM OPERATING ACTIVITIES	As on September 30, 2024	As at March 31, 2024
	Net Profit before taxation and extraordinary item	571.87	1,329.22
	Adjustment for:		
	Depreciation and amortization expense	68.62	130.23
	Finance Cost	124.08	299.71
	Interest received	-	-
	Dividend Received	-	-
	Profit/Loss on Sale of assets	-	-
	Profit/Loss on Sale of investments	-	-
	Provision for leave encashment and gratuity	-	-
	Provision for Diminution in value of Shares	-	-
	Miscellaneous Balance written off	-	-
	Inventory written off	-	-
	Operating Profit before Working Capital Changes	764.57	1,759.15
	Increase/Decrease in Inventory	(376.87)	(208.52)
	Increase/Decrease in Trade and Other Receivables	367.46	(1,808.31)
	Increase/Decrease in Short Term Loan and Advances	(343.04)	(39.45)
	Increase/Decrease in Current Assets	(17.76)	35.26
	Increase/Decrease in Trade Payables	(1,187.19)	(587.84)
	Cash generated from Operations	(792.82)	(849.71)
	Income Tax	-	(399.31)
	NET CASH FLOW FROM OPERATING ACTIVITIES	(792.82)	(1,249.03)
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Sale of investment	2.55	-
	Interest received	-	-
	Dividend received	-	-
	Purchase of Property, Plant and Equipment (Capital WIP)	(1,785.96)	(533.03)
	Issued Share Capital and Security Premium	-	3,494.97
	Purchase of Investment	-	-
	Sale of Asset	-	-
	Non-current other financial assets	361.24	(410.06)
	NET CASH FLOW FROM INVESTING ACTIVITIES	(1,422.16)	2,551.89
3	CASH FLOW FROM FINANCING ACTIVITIES		
	Increase/Decrease in Term Loan	807.19	18.30
	Increase/Decrease in WC	753.80	(166.90)
	Finance Cost	(124.08)	(299.71)
	NET CASH FLOW FROM FINANCING ACTIVITIES	1,436.91	(448.30)
	NET INCREASE IN CASH AND CASH EQUIVALENTS	(778.07)	854.56
	Cash and Cash Equivalents at the beginning of the period	874.29	19.73
	Cash and Cash Equivalents at the end of the period	96.22	874.29
		0.00	0.00

- The above Cash Flow has been compiled from and is based on the Balance sheet for the period ended on September, 30th 2024 and the related Profit & Loss Account for the period ended on September, 30th 2024.
- The above cash flow statement has been prepared under the Indirect Method as set out in the Accounting Standard-3 on Cash Flow Statement issued by The Institute of Chartered Accountants of India.
- Figures in parenthesis represent outflow.
- Previous year's figures have been regrouped, wherever necessary, to confirm current year's presentation.

For Zenith Drugs Limited

For Zenith Drugs Limited,

SANDEEP BHARDWAJ

Managing Director
(DIN: 00539347)

Director,

For Zenith Drugs Limited



Neeraj Pandey
CFO


Place: Indore

Date : 14/11/2024

Notes to Financial Reporting:

- 1) The above results have been prepared as per generally accepted accounting principles in India, prescribed u/s section 133 of the companies act 2013 and other recognized accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in accounting standard, as applicable, specified in section 133 of the companies act, 2013 read with relevant rules framed thereunder or as specified by the institute of chartered accountants of India, whichever is applicable.
- 2) The above un-audited standalone financial results of company for the half year ended 30th September, 2024 were reviewed and recommended by the audit committee and approved by the board of directors, at their respective meeting held on 14th November, 2024.
- 3) As the company's business activity falls within a single primary business segment, the disclosure requirements as per AS 17 "Segment Reporting" is not applicable.
- 4) The weighted average number of equities shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the accounting standard 20.
- 5) Previous period figures have been re-grouped and re-classified wherever necessary.
- 6) There are no investor's complaints pending as on 30th September, 2024.
- 7) The results of the company are also available for investors at www.zenithdrugs.com and www.nseindia.com.
- 8) The company has not adopted the Indian Accounting standards (IND AS) in terms of Exemption available to the companies Listed with SME.

For and on Behalf of the Board of Director of Zenith Drugs Limited


SANDEEP BHARDWAJ
Managing Director
(DIN: 00539347)


NEERAJ PANDEY
CFO

Place: Indore
Date: 14/11/2024